Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Purified CD4 T Lymphocyte Infusion Can Result in Graft-Versus-Leukemia Reactivity without Gvhd by Recognition of Broadly Expressed Minor Histocompatibility Antigens in HLA Class-II

P. van Balen, MD, C.A.M. van Bergen, I. Jedema, PhD, S.A.P. van Luxemburg-Heijs, J.C. Harskamp, H.M. van Egmond, S.A.J. Veld, M. Griffioen, PhD, W.A.F. Marijt, MD, PhD, C.J.M. Halkes, MD, PhD, J.H.F. Falkenburg, MD, PhD

Blood (2012) 120 (21): 4116.

https://doi.org/10.1182/blood.V120.21.4116.4116

Published: 2012

Journal Articles

HLA-Peptidomics and the Identification of Clinical Relevant Minor Histocompatibility Antigens,

Pleun Hombrink, MSc, Chopie Hassan, Michel G.D. Kester, Cornelis A.M. van Bergen, J.H.F. Falkenburg, MD, PhD, Peter A. van Veelen, Mirjam H.M. Heemskerk, PhD

Blood (2011) 118 (21): 4038.

https://doi.org/10.1182/blood.V118.21.4038.4038

Published: 2011

Journal Articles

Alemtuzumab Treatment Can Affect CD52 Positive As Well As CD52 Negative GPI-Deficient, Sezary Cells Allowing Long-Term Disease Control

C.J.M. Halkes, MD, PhD, I Jedema, PhD, H.M. van Egmond, L van der Fits, PhD, J.H.F. Falkenburg, MD, PhD, MH Vermeer, MD, PhD

Blood (2011) 118 (21): 2491.

https://doi.org/10.1182/blood.V118.21.2491.2491

Published: 2011

Journal Articles

In Vivo T Cell Depletion Using Rabbit Derived ATG Leads to An Increased EBV-PTLD Risk Due to An Induced Imbalance Between B and T Cell Recovery Which Is Not Seen After Horse Derived ATG or Alemtuzumab

C.J.M. Halkes, MD, PhD, J.H.F. Falkenburg, MD, PhD, H.M. van Egmond, J. Olde Wolbers, C.W.J. Starrenburg, P. van Balen, MD, M. van de Meent, P.A. von dem Borne, MD, PhD, W.A.F. Marijt, MD, PhD, J.H. Veelken, MD, PhD, I Jedema, PhD

Blood (2011) 118 (21): 1979.

https://doi.org/10.1182/blood.V118.21.1979.1979

Published: 2011

Journal Articles

Long-Term Disease-Free Survival of Patients with AML Relapse After T-Cell-Depleted Allogeneic Stem Cell Transplantation by Re-Induction Therapy and Subsequent Interferon-Boosted Donor Lymphocyte Infusion

M. Eefting, MD, C.J.M. Halkes, MD, PhD, S. Kersting, MD, PhD, W.A.F. Marijt, MD, PhD, P.A. von dem Borne, MD, PhD, J.H. Veelken, MD, PhD, J.H.F. Falkenburg, MD, PhD

Blood (2011) 118 (21): 3064.

https://doi.org/10.1182/blood.V118.21.3064.3064

Published: 2011

Journal Articles

Post-Transplant Immune Suppressive Therapy Is Not Necessary In Related and Unrelated Reduced Intensity Conditioning Stem Cell Transplantation Using Low Dose Alemtuzumab In Vivo T Cell Depletion Combined with Alemtuzumab-Mediated In Vitro T Cell Depletion of the Graft

P.A. Von Dem Borne, MD, PhD, C.J.M. Halkes, MD, PhD, C.W.J. Starrenburg, W.A.F. Marijt, MD, PhD, J.H.F. Falkenburg, MD, PhD

Blood (2010) 116 (21): 2328.

https://doi.org/10.1182/blood.V116.21.2328.2328

Published: 2010

Journal Articles

Retroviral Interference with Execution Pathways in Target Cells To Unravel Mechanisms of Cytotoxic T Cell-Mediated Cell Death.

J.F. de Vries, MSc, P.A. von dem Borne, MD, PhD, M.H.M. Heemskerk, PhD, R. Willemze, MD, PhD, J.H.F. Falkenburg, MD, PhD, R.M.Y. Barge, MD, PhD

Blood (2004) 104 (11): 1267.

https://doi.org/10.1182/blood.V104.11.1267.1267

Published: 2004

NARROW

Purified CD4 T Lymphocyte Infusion Can Result in Graft-Versus-Leukemia Reactivity without Gvhd by Recognition of Broadly Expressed Minor Histocompatibility Antigens in HLA Class-II

HLA-Peptidomics and the Identification of Clinical Relevant Minor Histocompatibility Antigens,

Alemtuzumab Treatment Can Affect CD52 Positive As Well As CD52 Negative GPI-Deficient, Sezary Cells Allowing Long-Term Disease Control

In Vivo T Cell Depletion Using Rabbit Derived ATG Leads to An Increased EBV-PTLD Risk Due to An Induced Imbalance Between B and T Cell Recovery Which Is Not Seen After Horse Derived ATG or Alemtuzumab

Long-Term Disease-Free Survival of Patients with AML Relapse After T-Cell-Depleted Allogeneic Stem Cell Transplantation by Re-Induction Therapy and Subsequent Interferon-Boosted Donor Lymphocyte Infusion

Post-Transplant Immune Suppressive Therapy Is Not Necessary In Related and Unrelated Reduced Intensity Conditioning Stem Cell Transplantation Using Low Dose Alemtuzumab In Vivo T Cell Depletion Combined with Alemtuzumab-Mediated In Vitro T Cell Depletion of the Graft

Retroviral Interference with Execution Pathways in Target Cells To Unravel Mechanisms of Cytotoxic T Cell-Mediated Cell Death.

Email alerts

ASH Publications

American Society of Hematology

Purified CD4 T Lymphocyte Infusion Can Result in Graft-Versus-Leukemia Reactivity without Gvhd by Recognition of Broadly Expressed Minor Histocompatibility Antigens in HLA Class-II

HLA-Peptidomics and the Identification of Clinical Relevant Minor Histocompatibility Antigens,

Alemtuzumab Treatment Can Affect CD52 Positive As Well As CD52 Negative GPI-Deficient, Sezary Cells Allowing Long-Term Disease Control

In Vivo T Cell Depletion Using Rabbit Derived ATG Leads to An Increased EBV-PTLD Risk Due to An Induced Imbalance Between B and T Cell Recovery Which Is Not Seen After Horse Derived ATG or Alemtuzumab

Long-Term Disease-Free Survival of Patients with AML Relapse After T-Cell-Depleted Allogeneic Stem Cell Transplantation by Re-Induction Therapy and Subsequent Interferon-Boosted Donor Lymphocyte Infusion

Post-Transplant Immune Suppressive Therapy Is Not Necessary In Related and Unrelated Reduced Intensity Conditioning Stem Cell Transplantation Using Low Dose Alemtuzumab In Vivo T Cell Depletion Combined with Alemtuzumab-Mediated In Vitro T Cell Depletion of the Graft

Retroviral Interference with Execution Pathways in Target Cells To Unravel Mechanisms of Cytotoxic T Cell-Mediated Cell Death.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only